Catalent agrees to biosimilar development collaboration with Zhejiang Hisun Pharma

April 7, 2014 10:30 AM

Catalent Pharma Solutions, the global provider of development solutions and advanced delivery technologies for drug, biologic and consumer health products, announced the signing of an agreement with Zhejiang HISUN Pharmaceuticals Co. Ltd. (HISUN), to provide HISUN with a broad range of biosimilar cell lines, using Catalent’s proprietary GPEx® technology for the Chinese market.

The development and manufacturing programs will benefit from the GPEx technology’s proven capability to produce very stable and high yielding cell lines.

Under the agreement, HISUN will produce a broad range of biosimilars, including infliximab, adalimumab and alemtuzumab, using Catalent’s GPEx cell lines.

Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business, commented, “We are keen to grow our biologics and development customer base throughout the Asia-Pacific region and intend to extend our global leadership in advanced delivery technologies and expert services throughout the region. We believe that the GPEx technology will enable HISUN to bring its products to market faster.”

Haibin Wang, Senior VP of HISUN, added, “As one of the leading pharma companies in China, we constantly evaluate technologies that can accelerate the progress of therapeutics for our patients. Catalent’s GPEx technology enables HISUN to bring its current bioreactor capacity to full operation, at a faster pace. We are excited about this collaboration because it heightens the quality and efficiency of our products’ development and enriches our pipeline products.”

In 2013, Catalent announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses to support customers within the Asia-Pacific region. Since then, the company has completed the acquisition of a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology Co. Ltd., and continues to invest in people and equipment to produce Catalent R P Scherer softgel technologies. Catalent’s new 31,000 sq ft facility in Shanghai opened on November 8th, 2013 and has become the first site in China to provide end-to-end solutions for clinical trial supplies.

Catalent’s proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency, getting drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production. Catalent has also exclusively licensed the SMARTag™ advanced antibody-drug conjugate technology and completed construction of its new single-use Biomanufacturing Center of Excellence in Madison, WI, USA.


Source: Catalent press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!